Sep 1, 2023 · Based on pathology findings, two types of human lung cancers have been identified so far: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is divided into squamous cell/epidermoid carcinoma, adenocarcinoma, and large cell carcinoma ( …

We sought to investigate the role and potential mechanism of MYC-induced long non-coding RNA (MINCR) in NSCLC. Expression levels of MINCR was first identified using The Cancer Genome Atlas (TCGA), further confirmed with specimens from 29 NSCLC patients and three cell lines using qRT-PCR.

Mar 3, 2019 · We analyzed MYC gene expression by qRT-PCR in 30 NSCLC patients’ samples and paired normal lung tissue. MYC expression was further statistically evaluated in relation to histopathological parameters, PHACTR3 and E2F4 gene alterations and survival.

We investigated the incidence of eukaryotic translation initiation factor 3 subunit H (EIF3H) and MYC amplification in non-small cell lung cancer (NSCLC) patients, and whether MYC/EIF3H increased gene copy number affected response to Epidermal Growth Factor Receptor tyrosine kinase inhibitors.

Capmatinib, a potent and selective mesenchymalepithelial transition factor (MET) inhibitor, is an effective treatment option for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations or gene amplification.

5 days ago · In non-small cell lung cancer, Selinexor induced a p53-dependent MYC downregulation that occurs independently of P53p53 mutational status in in vivo and in vitro studies as well . Similarly, KPT-185 administration in mantle cell lymphoma (MCL) cells suppresses the expression of XPO1 and MYC in a P53p53 mutation-independent pattern leading to ...

Apr 8, 2025 · Meanwhile, it has been reported that the enrichment of Myc target genes observed after knocking down IGF2BP3 and Myc is critical for tumor progression and drug resistance in NSCLC 47,48,49. Given ...

5 days ago · Enhances the stability of IGF2BP1, c-Myc and E2F1. Facilitates the c-Myc/MNX1-AS1/IGF2BP1 complex to accelerate cell cycle progression and promote lung cancer cell proliferation. ... drive gene expression programmes associated with cell proliferation, survival and invasion, ultimately contributing to non-small cell lung cancer (NSCLC ...

Enhanced macrophage M2 polarization and CD8 + T cell dysfunction contribute to the pathophysiology of non-small cell lung cancer (NSCLC). Motor neuron and pancreatic homeobox 1 (MNX1) has emerged as a potential tumor-promoting player. Here, we clarified the activity of MNX1 in NSCLC. ... N-Myc Proto-Oncogene Protein* / genetics

Sep 15, 2021 · Osimertinib (AZD9291 or TAGRISSO) is a promising and approved third-generation EGFR tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation.